Overview
Rothwell Figg has represented companies and research institutions operating in the research, development, and manufacturing of life sciences IP for decades. Our experience is both broad and deep and includes biologics and biosimilars, pharmaceuticals, biotechnology, medical devices, dental devices, environmental sciences, biomedical technologies, biomedicine, nutraceuticals, neuroscience, cell biology, biophysics, cosmeceuticals, and food processing, among others.
Our firm advises on the legal issues associated with new discoveries that range from personalized medicine and advancements in genetics and immune cell function to collaborative innovation among various life sciences companies, ensuring ownership of IP in the unprecedented momentum of life sciences research, particularly in drug discovery. Our experience includes advising on the IP inherent in issues such as accelerated demand for digitalized assessment, diagnosis, and treatment of patients and increased competition and value-based product pricing.
We also represent clients on cutting edge technology, including nucleic acid sequencing, detection, and modification (such as using the CRISPR/Cas system and other engineered nucleases). Our experience in antibody technology and biosimilars puts us at the forefront of complex, life-saving treatments. In addition, we advise clients regarding ongoing concerns surrounding data management, privacy, and cybersecurity.
Our lawyers understand patent law and technology and adapt quickly to developments in the law and the industry. We deliver a proven track record of successful results in practicing before the U.S. Patent and Trademark Office (USPTO), including preparation and prosecution, filing of appeals, and reissues and reexaminations. We are actively engaged in patent interferences, inter partes reviews (IPRs), and post-grant reviews (PGRs) at the USPTO Patent Trial and Appeal Board (PTAB). Our team is skilled in clearance reviews, due diligence initiatives, infringement and validity opinions, and the enforcement of life science patents at the district and federal circuit levels and before the International Trade Commission (ITC).
Our firm is a leader in resolving litigation arising out of the Drug Price Competition and Patent Term Restoration Act, referred to as Hatch-Waxman litigation. We have handled 60+ such cases in federal district courts and before the U.S. Court of Appeals for the Federal Circuit involving advanced legal and scientific theory. In addition, our advocates have challenged and defended scores of life sciences-related patents, successfully pursued antitrust cases arising out of the improper listing of patents in the Orange Book, and handled 60+ IPRs earning a depth of knowledge before the PTAB that is unique and expansive. We leverage this insight to help clients formulate a successful strategy on attack or defense.
Because many of our attorneys have scientific degrees in areas related to pharmaceuticals, including biomedical engineering, chemical engineering, biology, zoology, chemistry, biochemistry, molecular biology, neuroscience, and pharmacy, we function at the intersection of scientific intelligence and legal know-how.